Voyager Therapeutics stands out in the biotechnology industry for its pioneering work in gene therapy and neurology, particularly in overcoming delivery challenges that have historically limited the potential of these disciplines. The company's TRACER AAV capsid discovery platform, which has generated novel capsids with high target delivery and blood-brain barrier penetration, is not only advancing Voyager's own pipeline of preclinical programs in Parkinson's disease, Alzheimer's disease, and ALS, but also fueling partnerships with industry leaders like Pfizer, Novartis, and Neurocrine Biosciences. Voyager's commitment to diversity and collaboration further enhances its competitive edge, fostering an inclusive culture that values different perspectives and is dedicated to making discoveries that can change the course of medicine for patients.